SJT is a current recipient of a National Health and Medical Research Council (NHMRC) Postgraduate Research Scholarship. NDT is a current recipient of a Jacquot Foundation Research Establishment Award. The contents see more of this review article are solely the views of the individual authors and do not reflect the views of NHMRC or the Jacquot Foundation. “
“Malakoplakia is an unusual granulomatous inflammatory disorder associated with diminished bactericidal action of leucocytes that occurs in immunosuppressed hosts. Cases of renal allograft malakoplakia are generally associated with a poor graft and patient survival.

We present the case of a 56-year-old female with allograft and bladder malakoplakia occurring two years after renal transplantation complicated by an early antibody mediated rejection. Following a number of symptomatic urinary tract infections

caused by resistant Gram-negative bacilli, a diagnosis of malakoplakia was made by biopsy of a new mass lesion of the renal allograft. Cystoscopy also revealed malakoplakia of the bladder wall. Immunosuppressant regimen was modified. Mycophenolate mofetil was ceased, prednisolone reduced to 5 mg/day and tacrolimus concentrations were carefully monitored to maintain trough serum concentrations of 2–4 μg/L. Concurrently, she received a Pritelivir ic50 prolonged course of intravenous antibiotics followed by 13 months of dual oral antibiotic therapy with fosfomycin and faropenem. This joint approach resulted in almost complete resolution of allograft malakoplakia lesions and sustained regression of bladder lesions on cystoscopy with histological resolution in bladder lesions. Her renal function has remained stable throughout the illness. If treated with sustained antimicrobial therapy and reduction of immunosuppression, cases of allograft malakoplakia may not necessarily be associated with poor graft survival. We present the case C59 clinical trial of a 56-year-old South-East Asian woman with renal allograft and bladder malakoplakia. She received a cadaveric

renal transplant in March 2010 for IgA nephropathy. Prior to that she had received peritoneal dialysis for almost 4 years and underwent subtotal parathyroidectomy in October 2008. She was highly sensitized (Class 1 and 2 PRA 96%) due to earlier pregnancies and blood transfusions and the graft was mismatched at 6 of 6 HLA loci. Induction immunosuppression included basiliximab and IV methylprednisolone, followed by maintenance with tacrolimus (achieving trough levels 8.2–16.5 μg/L in the first month and 7–9 μg/L in the following 18 months), prednisolone (titrating down from 30 mg, once daily) and mycophenolate mofetil 720 mg, twice daily. She received Pneumocystis jirovecii (PJP) and cytomegalovirus prophylaxis with trimethoprim/sulfamethoxazole 800/160 mg, thrice weekly and valganciclovir 450 mg, daily for a period of 6 months.